Lynch Syndrome Linked to Increased Risk of Many Cancers

Share this article:
Lynch Syndrome Linked to Increased Risk of Many Cancers
Lynch Syndrome Linked to Increased Risk of Many Cancers

(HealthDay News) -- Patients with Lynch syndrome, an inherited disorder of cancer susceptibility caused by mutations in a mismatch repair (MMR) gene, face significantly increased risks of a variety of cancers, including breast and pancreatic cancer, according to a study published online Feb. 13 in the Journal of Clinical Oncology.

Aung Ko Win, M.B.B.S., M.P.H., from the University of Melbourne in Australia, and colleagues prospectively followed a cohort of 446 unaffected carriers of an MMR gene mutation (161 with MLH1; 222 with MSH2; 47 with MSH6; and 16 with PMS2) and 1,029 of their unaffected relatives who did not carry a mutation, with follow-up occurring every five years. Country-, age-, and sex-specific standardized incidence ratios (SIRs) of cancer for carriers and noncarriers were compared with the cancer risk of the general population.

The researchers found that, over a median of five years of follow-up, mutation carriers had a significantly increased risk of endometrial cancer (SIR, 30.62), colorectal cancer (SIR, 20.48), ovarian cancer (SIR, 18.81), renal cancer (SIR, 11.22), pancreatic cancer (SIR, 10.68), gastric cancer (SIR, 9.78), urinary bladder cancer (SIR, 9.51), and female breast cancer (SIR, 3.95). There was no evidence that noncarrier relatives had an elevated risk of any cancer.

"Our prospective analysis provides unbiased estimates of cancer risks for MMR gene mutation carriers, including significantly increased risks of recognized Lynch syndrome-associated cancers (colorectal, endometrial, ovarian, renal, gastric, and urinary bladder) and of breast cancer and pancreatic cancer," the authors write.

Abstract
Full Text

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

70-Gene signature not likely to be cost-effective for breast cancer

70-Gene signature not likely to be cost-effective for ...

Findings in comparative economic analysis of patients with node-negative breast cancer showed the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making.

Many clinicians feel mobile apps can improve patient outcomes

Many clinicians feel mobile apps can improve patient ...

Many physicians believe digital communication technologies, including mobile apps, can be of benefit to their patients.

Overdetection of PSA recurrence after radical prostatectomy more likely in older patients

Overdetection of PSA recurrence after radical prostatectomy more ...

For some men, prostate cancer recurrence may be overdetected, especially in those aged over 70.